Whole-exome sequencing identifies a set of genes as markers of hepatocellular carcinoma early recurrence

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  J. Yun,et al.  Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition) , 2020, Liver Cancer.

[3]  Zhenyu Zhang,et al.  MUC16 affects the biological functions of ovarian cancer cells and induces an antitumor immune response by activating dendritic cells , 2020, Annals of translational medicine.

[4]  Trushar R. Patel,et al.  Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma , 2020, World journal of gastroenterology.

[5]  Amanda J. Pickard,et al.  Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity , 2020, Nature Communications.

[6]  D. Pan,et al.  Expression of miR-145-3p in hepatocellular cancer and its regulatory effect on growth of hepatocellular cancer cells , 2020 .

[7]  Yuan Luo,et al.  MUC3A promotes non-small cell lung cancer progression via activating the NFκB pathway and attenuates radiosensitivity , 2020, International journal of biological sciences.

[8]  M. Kudo,et al.  Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[10]  Wei Wei,et al.  Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study , 2020, Frontiers in Oncology.

[11]  A. Villanueva,et al.  Tumour evolution in hepatocellular carcinoma , 2019, Nature Reviews Gastroenterology & Hepatology.

[12]  Ya Cao,et al.  Genomic Sequencing Identifies WNK2 as a Driver in hepatocellular carcinoma and a Risk Factor for Early Recurrence. , 2019, Journal of hepatology.

[13]  C. Fan,et al.  Genetic determinants of the molecular portraits of epithelial cancers , 2019, Nature Communications.

[14]  Motofumi Tanaka,et al.  Clinical Relevance of Reductive Hepatectomy for Barcelona Clinic Liver Cancer Stages B and C Advanced Hepatocellular Carcinoma: A Single-Center Experience of 102 Patients , 2019, World Journal of Surgery.

[15]  Mikel Hernaez,et al.  Sentieon DNASeq Variant Calling Workflow Demonstrates Strong Computational Performance and Accuracy , 2019, Front. Genet..

[16]  J. H. Kim,et al.  Hepatic resection compared to chemoembolization in intermediate‐ to advanced‐stage hepatocellular carcinoma: A meta‐analysis of high‐quality studies , 2018, Hepatology.

[17]  M. Mizuno,et al.  Mucin-producing hepatocellular carcinoma without morphological features of biliary differentiation , 2018, Medicine.

[18]  S. Choo,et al.  Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence , 2018, World journal of hepatology.

[19]  D. Xie,et al.  Overexpression of MUC13, a Poor Prognostic Predictor, Promotes Cell Growth by Activating Wnt Signaling in Hepatocellular Carcinoma. , 2017, The American journal of pathology.

[20]  Liang Li,et al.  Heterogeneity of liver cancer and personalized therapy. , 2016, Cancer letters.

[21]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, bioRxiv.

[22]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[23]  Hongyan Yuan,et al.  Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells. , 2015, The international journal of biochemistry & cell biology.

[24]  Hongyan Yuan,et al.  Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21WAF1 pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells , 2015, Oncotarget.

[25]  Hongyan Yuan,et al.  Impact of Mucin1 knockdown on the phenotypic characteristics of the human hepatocellular carcinoma cell line SMMC-7721. , 2014, Oncology reports.

[26]  Hong-Yang Wang,et al.  MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients. , 2013, Gastroenterology.

[27]  Chun-Che Lin,et al.  A rare cause of gastrointestinal bleeding. Multiple myeloma with extramedullary gastroduodenal plasmacytoma. , 2013, Gastroenterology.

[28]  T. Terada.  Combined hepatocellular-cholangiocarcinoma with stem cell features, ductal plate malformation subtype: a case report and proposal of a new subtype. , 2013, International journal of clinical and experimental pathology.

[29]  P. Deloukas,et al.  Mycobacterium bovis Requires P27 (LprG) To Arrest Phagosome Maturation and Replicate within Bovine Macrophages , 2013, BMC Genomics.

[30]  John Quackenbush,et al.  Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV , 2011, Bioinform..

[31]  Y. Nakanuma,et al.  Increased MUC6 apomucin expression is a characteristic of reactive biliary epithelium in chronic viral hepatitis , 1998, The Journal of pathology.